Qiagen NV

QIA

Company Profile

  • Business description

    Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).

  • Contact

    Hulsterweg 82
    VenloLI5912 PL
    NLD

    T: +31 773556600

    E: [email protected]

    https://www.qiagen.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Diagnostics & Research

    Fiscal Year End

    31 December 2025

    Employees

    5,700

Stocks News & Analysis

stocks

ASX reporting season wrap: BHP, banks, CSL bloodbath and more

A round up of notable stories and reactions as ASX earnings season continues.
stocks

Stock showdown: How do ASX healthcare giants compare on key investing criteria?

Our healthcare analyst Shane Ponraj helps me compare the moatiness and growth prospects of two sector heavyweights.
stocks

Peak profit for ASX listed insurer

Simplification plan complete, organic growth now the focus.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,234.3055.70-0.60%
CAC 407,969.6931.400.40%
DAX 4024,363.0969.750.29%
Dow JONES (US)45,631.74846.241.89%
FTSE 1009,321.4012.200.13%
HKSE25,339.14234.530.93%
NASDAQ21,496.54396.221.88%
Nikkei 22542,633.2923.120.05%
NZX 50 Index13,042.76151.31-1.15%
S&P 5006,466.9196.741.52%
S&P/ASX 2008,967.4057.00-0.63%
SSE Composite Index3,825.7654.661.45%

Market Movers